申联生物(688098) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥148,322,330.47, representing a year-over-year increase of 24.24%[4] - Net profit attributable to shareholders was ¥49,080,448.93, showing a slight increase of 3.39% compared to the same period last year[4] - The basic earnings per share for the quarter was ¥0.12, reflecting a decrease of 18.18% compared to the previous year[4] - Net profit for the third quarter of 2022 was ¥72,351,539.79, a decrease of 19.6% from ¥90,049,371.98 in the same quarter of 2021[18] - Basic earnings per share for the third quarter of 2022 were ¥0.18, down from ¥0.22 in the same period of 2021[18] - Total revenue for the first three quarters of 2022 reached ¥286,584,956.33, an increase of 5.4% compared to ¥272,415,976.87 in the same period of 2021[16] Research and Development - The total R&D expenditure for the quarter was ¥23,793,101.77, which is an increase of 117.73% year-over-year, accounting for 16.04% of total revenue[5] - Research and development expenses for the third quarter of 2022 were ¥26,393,024.56, an increase of 47.0% from ¥17,914,612.49 in the previous year[17] Assets and Liabilities - The company's total assets increased by 2.66% to ¥1,640,983,534.58 compared to the end of the previous year[5] - Total assets as of the end of the third quarter of 2022 amounted to ¥1,640,983,534.58, compared to ¥1,598,464,318.21 at the end of the third quarter of 2021[15] - Total liabilities increased to ¥126,878,877.83 in the third quarter of 2022, compared to ¥125,476,791.81 in the same period of 2021[15] Cash Flow - Cash flow from operating activities showed a significant decline of 395.61% year-to-date, primarily due to delayed payments from local animal epidemic prevention departments[8] - The net cash flow from operating activities was -41,221,111.53, a decrease from 13,944,598.26 in the previous quarter[21] - Cash inflow from investment activities totaled 1,570,790,119.34, compared to 2,723,589,766.03 in the prior quarter[21] - The net cash flow from investment activities was 59,062,990.00, a significant improvement from -12,187,583.03 in the previous quarter[21] - Cash outflow from financing activities was 36,932,899.32, slightly lower than 40,913,135.64 in the previous quarter[22] - The ending balance of cash and cash equivalents was 25,280,141.36, down from 82,949,840.46 in the previous quarter[22] Shareholder Information - The company reported a total of 10,614 common shareholders at the end of the reporting period[10] - The top shareholder, Yang Yufang, holds 90,063,197 shares, representing 21.93% of the total shares[10] - The total number of shares held by the top 10 shareholders accounts for 35.82% of the company's total shares[11] Inventory and Receivables - The total inventory as of September 30, 2022, was RMB 105,999,376.26, showing a slight increase from RMB 103,420,614.45 at the end of 2021[13] - Accounts receivable increased significantly to RMB 298,314,451.76, up from RMB 151,014,971.48, indicating a growth of about 97.8%[13] Other Information - The company has not disclosed any significant new product developments or technological advancements during the reporting period[12] - There were no significant mergers or acquisitions reported in the third quarter[12] - The company has not provided specific future guidance or outlook for the upcoming quarters[12]